Pharmacological characterization of 2NTX-99 [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N 3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide], a potential antiatherothrombotic agent with antithromboxane and nitric oxide donor activity in platelet and vascular preparations

Journal of Pharmacology and Experimental Therapeutics

Volumn 317, Issue 2, 2006, Pages 830-837

  Buccellati, Carola ^a   Sala, Angelo ^a   Rossoni, Giuseppe ^a   Capra, Valérie ^a   Rovati, G Enrico ^a   Di Gennaro, Antonio ^a   Folco, Giancarlo ^a,b   Colli, Susanna ^a   Casagrande, Cesare ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Faculty of Pharmacy   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2NTX 99; 4 METHOXY N 1 (4 NITROOXYCYCLOHEXYL) N 3 (3 PYRIDINYLMETHYL) 1,3 BENZENEDICARBOXAMIDE; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; COLLAGEN; INOSITOL PHOSPHATE; NITRIC OXIDE DONOR; NORADRENALIN; OZAGREL; PICOTAMIDE; PROSTACYCLIN; RECEPTOR SUBTYPE; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; THROMBOXANE B2; THROMBOXANE RECEPTOR BLOCKING AGENT; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA MEDIA; AREA UNDER THE CURVE; ARTICLE; ATHEROGENESIS; BLOOD CLOTTING; BLOOD VESSEL; BLOOD VESSEL WALL; CELL STRAIN HEK293; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CELL; MALE; MATHEMATICAL COMPUTING; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SMOOTH MUSCLE RELAXATION; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; THROMBOSIS; VASCULAR RING;

ADMINISTRATION, ORAL; ANIMALS; AORTA, THORACIC; ARACHIDONIC ACID; BENZAMIDES; BLOOD PLATELETS; CAROTID ARTERIES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; NITRIC OXIDE DONORS; PLATELET AGGREGATION; RABBITS; THROMBOXANES; VASODILATION;

EID: 33645883240     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.097170     Document Type: Article

References (40)

1. Ahlner J, Andersson RG, Torfgard K, and Axelsson KL (1991) Organic nitrate esters: clinical use and mechanisms of actions. Pharmacol Rev 43:351-423.
2. Antithrombotic Trialist Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324:71-86.
3. Antman EM, DeMets D, and Loscalzo J (2005) Cyclooxygenase inhibition and cardiovascular risk. Circulation 112:759-770.
4. Bhatt DL and Topol EJ (2003) Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2:15-28.
5. Bolla M, Almirante N, and Benedini F (2005) Therapeutic potential of nitrate esters of commonly used drugs. Curr Top Med Chem 5:707-720.
6. Bossant MJ, Ninio E, Delautier D, and Benveniste J (1990) Bioassay of paf-acether by rabbit platelet aggregation, in Methods in Enzymology (Murphy RC and Fitzpatrick FA eds) pp 125-130, Academic Press Inc., San Diego, CA.
7. Buccellati C, Ciceri P, Ballerio R, Casagrande C, Folco G, and Nicosia S (2002) Evaluation of the effects of anti-thromboxane agents in platelet-vessel wall interaction. Eur J Pharmacol 443:133-141.
8. Capra V, Habib A, Accomazzo MR, Ravasi S, Citro S, Levy-Toledano S, Nicosia S, and Rovati GE (2003) Thromboxane prostanoid receptor in human airway smooth muscle cells: a relevant role in proliferation. Eur J Pharmacol 474:149-159.
9. Capra V, Veltri A, Foglia C, Crimaldi L, Habib A, Parenti M, and Rovati GE (2004) Mutational analysis of the highly conserved ERY motif of the thromboxane A2 receptor: alternative role in G protein-coupled receptor signaling. Mol Pharmacol 66:880-889.
10. CAPRIE (1996) SCCAPRIE. Lancet 348:1329-1339.
11. Coto V, Oliviero U, Cocozza M, and Milani M (1998) Long-term safety and efficacy of picotamide, a dual-action antithromboxane agent, in diabetic patients with carotid atherosclerosis: a 6-year follow-up study. J Int Med Res 26:200-205.
12. Daiber A, Oelze M, Coldewey M, Bachschmid M, Wenzel P, Sydow K, Wendt M, Kleschyov AL, Stalleicken D, Ullrich V, et al. (2004) Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates. Mol Pharmacol 66:1372-1382.
13. De Caterina R, Giannessi D, Crea F, Chierchia S, Bernini W, Gazzetti P, and L'Abbate A (1984) Inhibition of platelet function by injectable isosorbide dinitrate. Am J Cardiol 53:1683-1687.
14. De Caterina R, Lombardi M, Bernini W, Mazzone A, Giannessi D, Moscarelli E, Weiss M, and Lazzerini G (1990) Inhibition of platelet function during in vivo infusion of isosorbide mononitrates: relationship between plasma drug concentration and hemodynamic effects. Am Heart J 119:855-862.
15. Dogne JM, de Leval X, Delarge J, David JL, and Masereel B (2000) New trends in thromboxane and prostacyclin modulators. Curr Med Chem 7:609-628.
16. Draper NR and Smith H (1966) Applied Regression Analysis. Wiley, New York.
17. Eikelboom JW and Hankey GJ (2004) Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice. Am J Cardiovasc Drugs 4:57-67.
18. Farndale RW, Sixma JJ, Barnes MJ, and de Groot PG (2004) The role of collagen in thrombosis and hemostasis. J Thromb Haemost 2:561-573.
19. Forbes CD (1998) Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination: ESPS Investigators: European Stroke Prevention Study. Thromb Res 92:S1-S6.
20. Fossati T, Parisi S, Abbiati G, and Castiglioni C (1992) Determination of picotamide in human plasma and urine by high-performance liquid chromatography. J Chromatogr 577:382-386.
21. Gresele P, Deckmyn H, Arnout J, Nenci GG, and Vermylen J (1989) Characterization of N,N′-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. Thromb Haemost 61:479-484.
22. Gresele P, Deckmyn H, Nenci GG, and Vermylen J (1991) Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol Sci 12:158-163.
23. Gurbel PA and Bliden KP (2003) Interpretation of platelet inhibition by clopidogrel and the effect of non-responders. J Thromb Haemost 1:1318-1319.
24. Habib A, Vezza R, Creminon C, Maclouf J, and FitzGerald GA (1997) Rapid, agonist-dependent phosphorylation in vivo of human thromboxane receptor isoforms. Minimal involvement of protein kinase C. J Biol Chem 272:7191-7200.
25. Hanson J, Rolin S, Reynaud D, Qiao N, Kelley LP, Reid HM, Valentin F, Tippins J, Kinsella BT, Masereel B, et al. (2005) In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N′-[2-(4′-methylphenylamino)-5-nitrobenzenesulfonyl] urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist. J Pharmacol Exp Ther 313:293-301.
26. Maclouf J, Folco G, and Patrono C (1998) Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in cardiovascular disease. Thromb Haemost 79:691-705.
27. Megson IL (2000) Nitric oxide donor drugs. Drugs Future 25:701-715.
28. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht HJ, Zhao F, Chrolavicius S, et al. (2001) Cure Study Investigators. Lancet 358:527-533.
29. Modesti P (1995) Picotamide: an inhibitor of the formation and effects of TXA2. Cardiovasc Drug Rev 13:353-364.
30. Moncada S, Palmer RM, and Higgs EA (1991) Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43:109-142.
31. Munson PJ and Rodbard D (1980) Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220-239.
32. Napoli C, Aldini G, Wallace JL, de Nigris F, Maffei R, Abete P, Bonaduce D, Condorelli G, Rengo F, Sica V, et al. (2002) Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proc Natl Acad Sci USA 99:1689-1694.
33. Napoli C and Ignarro LJ (2001) Nitric oxide and atherosclerosis. Nitric Oxide 5:88-97.
34. Neri Serneri GG, Coccheri S, Marubini E, and Violi F (2004) Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 25:1845-1852.
35. Nowak J and FitzGerald GA (1989) Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man. J Clin Investig 83:380-385.
36. Pradelles P, Grassi J, and Maclouf J (1985) Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Anal Chem 57:1170-1173.
37. Reilly IA and FitzGerald GA (1987) Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69:180-186.
38. Tremoli E, Maderna P, Colli S, Morazzoni G, Sirtori M, and Sirtori CR (1984) Increased platelet sensitivity and thromboxane B2 formation in type-II hyperlipoproteinaemic patients. Eur J Clin Investig 14:329-333.
39. Walford G and Loscalzo J (2003) Nitric oxide in vascular biology. J Thromb Haemost 1:2112-2118.
40. Weber AA, Strobach H, and Schror K (1993) Direct inhibition of platelet function by organic nitrates via nitric oxide formation. Eur J Pharmacol 247:29-37.